Allogene reports updated Phase 1 data for ALLO-501/501A in r/r LBCL with 58% ORR and 42% CR

Allogene Therapeutics, Inc.

In 33 CAR T-naïve patients, ORR 58%, CR 42%; 30% maintained CR at 6 months across all patients.
Phase 2 regimen (12 patients): ORR 67%, CR 58%; median duration of response 23.1 months.
No Grade ≥3 CRS, no ICANS or GvHD; cytopenia and infections manageable, comparable to autologous CAR T.
Company expects to complete enrollment of potentially pivotal Phase 2 ALPHA2 trial in 1H2024; plans to open sites in Europe, Canada, Australia in 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.